Literature DB >> 30792201

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Othman Al-Sawaf1, Carmen Diana Herling1, Udo Holtick1, Christoph Scheid1, Paula Cramer1, Stephanie Sasse1, Bastian von Tresckow1, Armin Tuchscherer1, Kirsten Fischer1, Barbara Eichhorst1, Michael Hallek1, Lukas P Frenzel2.   

Abstract

Entities:  

Year:  2019        PMID： 30792201      PMCID： PMC6518913          DOI： 10.3324/haematol.2018.212837

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Authors:  C S Link; R Teipel; F Heidenreich; E Rücker-Braun; M Schmiedgen; J Reinhardt; U Oelschlägel; M von Bonin; J M Middeke; A Muetherig; K Trautmann-Grill; U Platzbecker; M Bornhäuser; J Schetelig
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

2.  Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Authors:  Uri Rozovski; Ohad Benjamini; Preetesh Jain; Philip A Thompson; William G Wierda; Susan O'Brien; Jan A Burger; Alessandra Ferrajoli; Stefan Faderl; Elizabeth Shpall; Chitra Hosing; Issa F Khouri; Richard Champlin; Michael J Keating; Zeev Estrov
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

3.  Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.

Authors:  Isabelle Krämer; Stephan Stilgenbauer; Sascha Dietrich; Sebastian Böttcher; Matthias Zeis; Michael Stadler; Jörg Bittenbring; Lutz Uharek; Christof Scheid; Ute Hegenbart; Anthony Ho; Michael Hallek; Michael Kneba; Norbert Schmitz; Hartmut Döhner; Peter Dreger
Journal:  Blood       Date:  2017-07-17       Impact factor: 22.113

4.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Authors:  David Miklos; Corey S Cutler; Mukta Arora; Edmund K Waller; Madan Jagasia; Iskra Pusic; Mary E Flowers; Aaron C Logan; Ryotaro Nakamura; Bruce R Blazar; Yunfeng Li; Stephen Chang; Indu Lal; Jason Dubovsky; Danelle F James; Lori Styles; Samantha Jaglowski
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

5.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

Review 6.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Authors:  Peter Dreger; Johannes Schetelig; Niels Andersen; Paolo Corradini; Michel van Gelder; John Gribben; Eva Kimby; Mauricette Michallet; Carol Moreno; Stephan Stilgenbauer; Emili Montserrat
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

Review 7.  Chronic lymphocytic leukaemia.

Authors:  Michael Hallek; Tait D Shanafelt; Barbara Eichhorst
Journal:  Lancet       Date:  2018-02-21       Impact factor: 79.321

Review 8.  High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

Authors:  Peter Dreger; Paolo Ghia; Johannes Schetelig; Michel van Gelder; Eva Kimby; Mauricette Michallet; Carol Moreno; Tadeusz Robak; Stephan Stilgenbauer; Emili Montserrat
Journal:  Blood       Date:  2018-07-11       Impact factor: 22.113

9.  Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Peter Hillmen; John F Seymour; Steven Coutre; Wojciech Jurczak; Stephen P Mulligan; Anna Schuh; Sarit Assouline; Clemens-Martin Wendtner; Andrew W Roberts; Matthew S Davids; Johannes Bloehdorn; Talha Munir; Sebastian Böttcher; Lang Zhou; Ahmed Hamed Salem; Monali Desai; Brenda Chyla; Jennifer Arzt; Su Young Kim; Maria Verdugo; Gary Gordon; Michael Hallek; William G Wierda
Journal:  J Clin Oncol       Date:  2018-05-01       Impact factor: 44.544

10.  Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance.

Authors:  Sarah Sharon Gabriel; Nina Bon; Jin Chen; Thomas Wekerle; Andrew Bushell; Thomas Fehr; Pietro Ernesto Cippà
Journal:  Front Immunol       Date:  2016-03-01       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.